ストックスクリーナーアプリを入手
32.84
1.51%
0.49
アフターアワーズ：
32.90
0.06
+0.18%
Maze Therapeutics Inc (MAZE) 最新ニュース
[Form 4] Maze Therapeutics, Inc. Insider Trading Activity - Stock Titan
Maze Therapeutics (MAZE) CEO’s family trusts sell 34,501 shares under 10b5-1 plan - Stock Titan
Enterprise value to EBITDA forward of Maze Therapeutics, Inc. – NASDAQ:MAZE - TradingView
Form 144 Maze Therapeutics For: 1 July By Investing.com - Investing.com UK
Form 4 Maze Therapeutics Inc For: 1 July By Investing.com - Investing.com Nigeria
MAZE (NASDAQ: MAZE) sale notice: 46,892 shares via option exercise - Stock Titan
Maze Therapeutics CSBO Atul Dandekar sells $210,150 in shares - Investing.com
Maze Therapeutics CSBO Atul Dandekar sells $210,150 in shares By Investing.com - Investing.com South Africa
Maze Therapeutics (MAZE) CSBO sells 7,500 shares under Rule 10b5-1 plan - Stock Titan
MAZE (MAZE) trusts sell tens of thousands of common shares May–June 2026 - Stock Titan
Maze Therapeutics (MAZE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España
Enterprise value to revenue forward of Maze Therapeutics, Inc. – NASDAQ:MAZE - TradingView
Maze Therapeutics (MAZE) Gains 2.18% as Shares Test Key Resistance at $30.5Volatility Stop - dars.gov.et
Price to book forward of Maze Therapeutics, Inc. – BOATS:MAZE - TradingView
Price to earnings forward of Maze Therapeutics, Inc. – NASDAQ:MAZE - TradingView
Enterprise value to revenue forward of Maze Therapeutics, Inc. – BOATS:MAZE - TradingView
What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors? - Yahoo Finance
Maze Therapeutics (MAZE) Rebounds This Week, Is The Upside Already Priced In? - Sahm
MAZE Forecast — Price Target — Prediction for 2027 - TradingView
GHRS Stock Price and Chart — NASDAQ:GHRS - TradingView
Maze Therapeutics, Inc. Actuals & Estimates (NASDAQ:MAZE) - TradingView
MAZE Stock Price, Quote & Chart - ChartMill
Maze Therapeutics Inc (MAZE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Maze Therapeutics (MAZE) CEO sells 27,858 shares under 10b5-1 trading plan - Stock Titan
Maze Therapeutics Inc (MAZE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Maze Therapeutics Inc (MAZE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Mizuho Securities Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $97 - Moomoo
Analyst Reaffirms Buy on Maze with Unchanged $110 Price Target, Citing Strong HORIZON Data and Favorable Risk-Reward - TipRanks
H.C. Wainwright Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $110 - Moomoo
Maze Therapeutics (MAZE) price target increased by 11.37% to 44.12 - MSN
Maze Therapeutics (MAZE) Gains 3.38% as Biotech Stock Tests Key Resistance LevelsFibonacci Entry Signals - dars.gov.et
Maze Therapeutics Inc (MAZE) Institutional Confidence - TradingKey
Maze Therapeutics Inc (MAZE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Maze Therapeutics Inc (MAZE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Maze Therapeutics Inc (MAZE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Maze Therapeutics Inc (MAZE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Maze Therapeutics Inc (MAZE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MAZE Q1 2026 Earnings: Narrowing Loss Beats Estimates as Pre-Revenue Biotech Focuses on Pipeline ProgressGuidance Revision Trend - newsline.com
Maze Therapeutics Phase 2 Kidney Data Sparks Questions On Upside And Risk - Yahoo Finance
MAZE Q1 2026 Earnings: Narrower Loss Surprises Analysts Amid Pipeline ProgressEarnings Acceleration Picks - lwvtexas.org
MAZE Q1 2026 Earnings: Smaller-Than-Expected Loss Drives Positive Stock ReactionEPS Revision Trend - newsline.com
Maze Therapeutics Shareholders Elect Directors, Ratify Auditor - TipRanks
Maze Therapeutics (MAZE) director receives grant of 18,000 stock options exercisable at $23.58 - Stock Titan
Director Richard Scheller receives 18,000 Maze Therapeutics (MAZE) stock options - Stock Titan
Maze Therapeutics (MAZE) director Herve Hoppenot awarded 18,000 stock options at $23.58 - Stock Titan
18,000 Maze Therapeutics (MAZE) options granted to director Andrews - Stock Titan
Maze Therapeutics (MAZE) shareholders elect directors and ratify Ernst & Young - Stock Titan
MAZE: Lead assets show strong efficacy and safety, with pivotal trials and key data readouts set for 2026–2027 - TradingView
MAZE: Directors and auditor ratified by majority vote; no shareholder questions submitted - TradingView
MAZE: Both director nominees and the auditor appointment were approved by majority vote - TradingView
MAZE Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift StockBasic EPS Analysis - newsline.com
Maze Therapeutics (MAZE): 8 Oversold Stocks to Buy Right Now - Insider Monkey
1.17%
2.48%
大文字化:
|
ボリューム (24 時間):